These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31871076)

  • 41. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam during high volume haemodiafiltration in patients with septic shock.
    Tamme K; Oselin K; Kipper K; Tasa T; Metsvaht T; Karjagin J; Herodes K; Kern H; Starkopf J
    Acta Anaesthesiol Scand; 2016 Feb; 60(2):230-40. PubMed ID: 26830215
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Population pharmacokinetics of piperacillin in critically ill children including those undergoing continuous kidney replacement therapy.
    Butragueño-Laiseca L; Marco-Ariño N; Troconiz IF; Grau S; Campillo N; García X; Padilla B; Fernández SN; Slöcker M; Santiago MJ
    Clin Microbiol Infect; 2022 Sep; 28(9):1287.e9-1287.e15. PubMed ID: 35390523
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Urinary piperacillin/tazobactam pharmacokinetics in vitro to determine the pharmacodynamic breakpoint for resistant Enterobacteriaceae.
    Gould M; Ginn AN; Marriott D; Norris R; Sandaradura I
    Int J Antimicrob Agents; 2019 Aug; 54(2):240-244. PubMed ID: 31108222
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.
    Roger C; Cotta MO; Muller L; Wallis SC; Lipman J; Lefrant JY; Roberts JA
    Int J Antimicrob Agents; 2017 Aug; 50(2):227-231. PubMed ID: 28689876
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients.
    Patel N; Scheetz MH; Drusano GL; Lodise TP
    Antimicrob Agents Chemother; 2010 Jan; 54(1):460-5. PubMed ID: 19858253
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial.
    De Waele JJ; Carrette S; Carlier M; Stove V; Boelens J; Claeys G; Leroux-Roels I; Hoste E; Depuydt P; Decruyenaere J; Verstraete AG
    Intensive Care Med; 2014 Mar; 40(3):380-7. PubMed ID: 24356862
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Individualizing piperacillin/tazobactam dosing in adult patients with cystic fibrosis: can tobramycin measurements help?
    Crass RL; Pai MP; Lodise TP
    J Antimicrob Chemother; 2019 Jan; 74(1):126-129. PubMed ID: 30252050
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Personalised antibiotic therapy in a surgical intensive care unit overview of current knowledge and the results of an observational kinetic study].
    Kaška M; Martinková J; Havel E; Kočí J; Fousková A; Solichová D; Kujovská L; Selke-Krulichová I; Práznovec I; Salavec V
    Rozhl Chir; 2014 Sep; 93(9):456-62. PubMed ID: 25301344
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Population pharmacokinetics and pharmacodynamics of piperacillin in critically ill patients during the early phase of sepsis.
    Sukarnjanaset W; Jaruratanasirikul S; Wattanavijitkul T
    J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):251-261. PubMed ID: 30963365
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-β-Lactamase-Producing
    Abodakpi H; Chang KT; Gao S; Sánchez-Díaz AM; Cantón R; Tam VH
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530606
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics/pharmacodynamics analysis and establishment of optimal dosing regimens using unbound cefmetazole concentration for patients infected with Extended-Spectrum β-lactamase producing Enterobacterales (ESBL-E).
    Namiki T; Yokoyama Y; Hashi H; Oda R; Jibiki A; Kawazoe H; Matsumoto K; Suzuki S; Nakamura T
    Pharmacotherapy; 2024 Feb; 44(2):149-162. PubMed ID: 37984818
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of a Real-Time TDM-Based Expert Clinical Pharmacological Advice Program in Optimizing the Early Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Beta-Lactams among Orthotopic Liver Transplant Recipients with Documented or Suspected Gram-Negative Infections.
    Gatti M; Rinaldi M; Laici C; Siniscalchi A; Viale P; Pea F
    Antibiotics (Basel); 2023 Nov; 12(11):. PubMed ID: 37998801
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Plasma pharmacokinetics of ceftolozane/tazobactam in pediatric patients with cystic fibrosis.
    Arrieta AC; Ang JY; Zhang Z; Larson KB; Yu B; Johnson MG; Rhee EG; Feng EH; Rizk ML
    Pediatr Pulmonol; 2020 Aug; 55(8):2025-2032. PubMed ID: 32421928
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Piperacillin/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: an in silico pharmacokinetic study.
    Guet-Revillet H; Tomini E; Emirian A; Join-Lambert O; Lécuyer H; Zahar JR; Jullien V
    Int J Antimicrob Agents; 2017 Jan; 49(1):62-66. PubMed ID: 27876276
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing.
    Gatti M; Giannella M; Raschi E; Viale P; De Ponti F
    J Antimicrob Chemother; 2021 Jan; 76(1):199-205. PubMed ID: 33057628
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics and Pharmacodynamics of Extended Infusion Versus Short Infusion Piperacillin-Tazobactam in Critically Ill Patients Undergoing CRRT.
    Shotwell MS; Nesbitt R; Madonia PN; Gould ER; Connor MJ; Salem C; Aduroja OA; Amde M; Groszek JJ; Wei P; Taylor ME; Tolwani AJ; Fissell WH
    Clin J Am Soc Nephrol; 2016 Aug; 11(8):1377-1383. PubMed ID: 27197907
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.
    Awissi DK; Beauchamp A; Hébert E; Lavigne V; Munoz DL; Lebrun G; Savoie M; Fagnan M; Amyot J; Tétreault N; Robitaille R; Varin F; Lavallée C; Pichette V; Leblanc M
    Pharmacotherapy; 2015 Jun; 35(6):600-7. PubMed ID: 26095008
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
    Peng Y; Cheng Z; Xie F
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0082222. PubMed ID: 36005753
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetic/pharmacodynamic predictions and clinical outcomes of patients with augmented renal clearance and
    Gerlach AT; Wenzler E; Hunt LN; Bazan JA; Bauer KA
    Int J Crit Illn Inj Sci; 2019; 9(3):138-143. PubMed ID: 31620353
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Scaling beta-lactam antimicrobial pharmacokinetics from early life to old age.
    Lonsdale DO; Baker EH; Kipper K; Barker C; Philips B; Rhodes A; Sharland M; Standing JF
    Br J Clin Pharmacol; 2019 Feb; 85(2):316-346. PubMed ID: 30176176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.